ACADIA Pharmaceuticals (ACAD) is off 3.5% postmarket after filing a shelf registration. The S-3 relates to the disposition from time to time of up to just
ACAD earnings call for the period ending March 31, 2019.
ACADIA Pharmaceuticals (ACAD) Q1 results ($M): NUPLAZID sales: 63.0 (+28.8%). Net loss: (85.3) (-57.1%); loss/share: (0.59) (-31.8%). 2019 guidance: NUPLAZ
6 Stock Market Predictions For The Week Of June 10 S&P 500 (SPY) Stocks will try to pick up where they left off the week of June 10 and they have a good chance of rising...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Buy||Strong Buy||Buy||Buy|
|Technical Indicators||Strong Sell||Neutral||BUY||Sell||Strong Buy|
|Summary||Strong Sell||Neutral||Strong Buy||Neutral||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Engulfing Bearish||1M||2||Apr 19|
|Homing Pigeon||5H||2||Jun 17, 2019 05:00AM|
|Deliberation Bearish||1M||3||Mar 19|
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.Read More
|Cyprus Securities and Exchange Commission (Cyprus), The Financial Conduct Authority (United Kingdom), Australian Securities and Investments Commission (Australia)||$200||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.